Arca
Skip to content
Tools
Tools

Canada Clinical Trial Authorizations

Before a drug trial can start in Canada, Health Canada has to authorize it with a No Objection Letter. Its database lists every authorized trial since 2013 and the company behind each one, including trials that never appear in US registries.

All 9,774 drug trials Health Canada has authorized since 2013, through Nov 13, 2026, with each trial's sponsor, investigational products and conditions.

  • Authorized, last 12 months: 683
  • Ongoing: 4,563
  • Authorized since 2013: 9,774

Trials authorized per year

By the date of Health Canada's No Objection Letter.

How to read this

A hatched bar is a year that is not over, so its count covers only part of the year.

  • Full year
  • 2013 to date

Top sponsors, 2024 to 2026

Company groups, by the products' Canadian sponsor.

Top conditions, 2024 to 2026

As Health Canada lists them; a trial can have several.

Every authorized trial

The last two years, newest first; searching or filtering loads every trial since 2013. Sponsors with FDA records link to their company page.

1,426 trials

Nov 13, 2026Follow-up to a phase 2 trial to evaluate the safety and immunological effects of short-course DM-101PX in adults with birch pollen-induced allergic rhinitis orโ€ฆDM-101PX ยท Seasonal allergic rhinitis ยท Rhinoconjuctivitis ยท Protocol DM-101-C-006 (C2D07557)Desentum OyPending
Nov 13, 2026A phase 3 randomized, double-blind, placebo-controlled, multicenter study to determine the efficacy and safety of ulviprubart in the treatment of participantsโ€ฆUlviprubart (ABC008) ยท Inclusion body myositis ยท Protocol ABC008-IBM-301Abcuro IncPending
Nov 13, 2026A phase 1, randomized, double-blinded, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, andโ€ฆEPRA-0322 ยท Anemia ยท Chronic kidney disease (CKD) ยท Protocol EPK-0322-101 (5863-04)Epok Therapeutics Inc.Pending
Nov 13, 2026A phase 2a, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of MK-8690 in participants with rheumatoid arthritisMK-8690 ยท Rheumatoid arthritis ยท Protocol MK-8690-004Merck & Co. (MSD)Pending
Nov 13, 2026Dualis: a modular phase I/ii, open-label, multicentre study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, andโ€ฆAZD1221 ยท Hematological malignancies ยท Protocol D7920C00001AstraZeneca PharmaceuticalsPending
Nov 13, 2026A phase 3 randomized open-label study to evaluate the safety and efficacy of risvutatug rezetecan in combination with atezolizumab in participants with newlyโ€ฆRisvutatug rezetecan (GSK5764227) ยท Small cell lung cancer ยท Protocol 300599GSKPending
Nov 12, 2026Hidradenitis suppurativa: a phase 2 multicenter platform study of targeted therapies for the treatment of adult subjectsABBV-295 / Lutikizumab (ABT-981) ยท Hidradenitis suppurativa ยท Protocol M26-508AbbViePending
Nov 10, 2026A phase 2b, multicenter, randomized, double-blind, parallel-group, placebo-controlled, dose range finding study to evaluate the efficacy, safety, andโ€ฆCSL787 ยท Non-cystic fibrosis bronchiectasis ยท Protocol CSL787_2001CSLPending
Nov 6, 2026A phase 1 open-label, multicenter study to evaluate the safety, tolerability and pharmacokinetics of MK-1568 as monotherapy in participants with metastaticโ€ฆMK-1568 ยท Prostate cancer metastatic castrationโ€ฆ ยท Protocol MK-1568-001Merck & Co. (MSD)Pending
Nov 5, 2026An investigation of the effect of subcutaneous zenagamtide on pharmacokinetics of an oral combination contraceptive (ethinylestradiol and levonorgestrel) andโ€ฆZenagamtide (NNC0487-0111) / Portia (ethinyl estradiol / Levonorgestrel) /โ€ฆ ยท Overweight/obesity ยท Protocol NN9490-8154Novo NordiskPending
Nov 5, 2026An open-label, phase 1b study to evaluate the safety of VERVE-301 in patients with elevated lipoprotein(a)VERVE-301 (LY4354070) ยท Elevated levels of lipoprotein ยท Protocol VT-30101Verve Therapeutics, Inc., A Wholly Owned Subsidiary of Eli Lilly and CompanyPending
Nov 3, 2026A rollover study to evaluate the safety, tolerability, and efficacy of long-term trontinemab administration in participants with Alzheimer's diseaseTrontinemab (RO7126209) / Lantheus ([18F]MK-6240) ยท Alzheimer's disease ยท Protocol WN45890RochePending
Oct 30, 2026A phase 2/3 multi-arm, open-label study of MK-1045 in combination with zilovertamab vedotin in participants with relapsed/refractory diffuse large B-cellโ€ฆMK-1045 / Zilovertamab vedotin (MK-2140) ยท Diffuse large B-cell lymphoma ยท Protocol MK-1045-010Merck & Co. (MSD)Pending
Oct 30, 2026Solara: a phase 3 study of the efficacy and safety of sutacimig in participants with Glanzmann thrombastheniaSutacimig (HMB-001) ยท Glanzmann thrombasthenia ยท Protocol HMB-001-103Hemab Therapeutics Inc.Pending
Oct 30, 2026A phase 3 study evaluating sacituzumab tirumotecan plus subcutaneous pembrolizumab and berahyaluronidase alfa (MK-3475A) as induction therapy, followed byโ€ฆMK-2870 / Keytruda sc (MK-3475A) ยท Muscle-invasive bladder cancer ยท Protocol MK-2870-055Merck & Co. (MSD)Pending
Oct 30, 2026An open-label, rollover study for participants with thyroid eye disease previously enrolled in amgen-sponsored amg 732 studies and are primary proptosisโ€ฆAmg 732 ยท Thyroid eye disease ยท Protocol 20230294AmgenPending
Oct 30, 2026A phase 3, randomized, double-masked, parallel group, placebo-controlled, multicenter study to evaluate the efficacy, safety, pharmacokinetics,โ€ฆKlygefa (gefurulimab (ALXN1720)) ยท Myasthenia gravis ยท Protocol ALXN1720-OMG-303AstraZeneca PharmaceuticalsPending
Oct 29, 2026A phase 2, open-label, master protocol study to evaluate safety and efficacy of treatment combinations with telisotuzumab adizutecan in subjects withโ€ฆTelisotuzumab adizutecan (ABBV-400) / Gemcitabine ยท Pancreatic cancer ยท Biliary cancer ยท Protocol M26-118AbbViePending
Oct 29, 2026A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sotatercept in adults with combined postcapillary andโ€ฆWinrevair (sotatercept (MK-7962)) ยท Pre- and post-capillary pulmonaryโ€ฆ ยท Heart failure ยท Protocol MK-7962-041Merck & Co. (MSD)Pending
Oct 29, 2026A phase 3 multicenter, randomized, open-label study evaluating the safety and efficacy of etentamig (ABBV-383) compared to daratumumab, cyclophosphamide,โ€ฆEtentamig (ABBV-383) ยท Amyloidosis ยท Protocol M24-473AbbViePending
Oct 28, 2026Endeavor: a clinical study to evaluate the safety and efficacy of ETX101, an AAV9-delivered gene therapy in infants and children with SCN1A-positive Dravetโ€ฆETX101 ยท Dravet syndrome ยท Protocol ETX-DS-002Encoded Therapeutics, Inc.Pending
Oct 27, 2026Luna-2: a phase II randomized trial of LND101 for fecal microbiota transplantation in combination with immune checkpoint blockade and chemotherapy inโ€ฆLND101 ยท Non-small cell lung cancer ยท Protocol BR.39Canadian Cancer Trials Group, Cancer Research Institute, Queen's UniversityPending
Oct 23, 2026A randomised, double-blind, placebo-controlled phase IIa trial to evaluate the efficacy, pharmacokinetics, pharmacodynamics, safety, and tolerability of biโ€ฆBI 3810477 ยท Idiopathic pulmonary fibrosis (IPF) ยท Protocol 1530-0005Boehringer Ingelheim (Canada) Ltd LteePending
Oct 23, 2026A phase 1-1b study to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [177lu]LU-A9-0631 and [225ac]AC-A9-0642 in participants withโ€ฆ[177LU]LU-A9-0631 injection / [225AC]AC-A9-0642 injection / [68GA]GA-A9-6217โ€ฆ ยท Tumor ยท Protocol A9-0600-01ALPHA-9 Oncology USA Inc.Pending
Oct 23, 2026Master protocol: MK-2870-U01 master protocol: a phase 1/2 platform study to evaluate the safety and efficacy of sacituzumab tirumotecan (sac-tmt; MK-2870) asโ€ฆMK-2870 (sacituzumab tirumotecan) / Opevesostat (MK-5684) / Abiraterone acetateโ€ฆ ยท Prostate cancer ยท Protocol MK-2870-U01Merck & Co. (MSD)Pending
Oct 22, 2026A phase 3, randomized, open-label, multicenter trial of amivantamab as sequential therapy following definitive, platinum-based, concurrent chemoradiotherapy,โ€ฆRybrevant (AMIVANTAMAB0 ยท Squamous cell carcinoma of the head andโ€ฆ ยท Protocol 61186372HNC3002Johnson & JohnsonPending
Oct 22, 2026A multicnter, randomized, double-blind, placebo controlled program consisting of a phase 2b trial and phase 3 trial to evaluate the efficacy and safety ofโ€ฆTEV-53408 ยท Vitiligo ยท Protocol TV53408-IMM-30105Teva Canada LimitedPending
Oct 22, 2026Rosetta LUNG-220: a phase 2, open-label, multicenter, multi-arm platform study evaluating pumitamig and other novel neoadjuvant regimens in participants withโ€ฆPumitamig (BMS-986545; BNT327) ยท Non-small cell lung cancer ยท Protocol CA2660020Bristol-Myers SquibbPending
Oct 21, 2026A global, interventional, open-label trial of t-dxd-based therapy followed by palbociclib, endocrine therapy and dual HER2 blockade in first-line HER2+/HR+โ€ฆEnhertu / Arimidex / Aromasin / Faslodex / Femara / Ibrance / Perjeta / Herzumaโ€ฆ ยท Breast cancer HER2-positive ยท Breast cancer metastatic ยท Protocol DS8201-0004-CIS-MADaiichi SankyoPending
Oct 20, 2026A phase 3, multicenter, open-label, randomized study to evaluate inobrodib in combination with pomalidomide and dexamethasone versus standard available therapyโ€ฆInobrodib (CCS1477) / Pomalidomide / Dexamethasone / Darzalex (daratumumab) /โ€ฆ ยท Multiple myeloma ยท Protocol CCS1477-05Cellcentric LtdPending
Oct 16, 2026A phase 1b/2, open-label study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of MK-2750 monotherapy in participants withโ€ฆMK-2750 ยท Advanced solid tumors ยท Protocol MK-2750-002Merck & Co. (MSD)Pending
Oct 16, 2026A phase 3, open label, randomized study comparing the efficacy and safety of odronextamab (REGN1979), an ANTI-CD20 ร— ANTI-CD3 bispecific antibody, inโ€ฆOdronextamab (REGN1979) ยท Diffuse large B-cell lymphoma ยท Protocol R1979-ONC-2105RegeneronPending
Oct 16, 2026Novel endovascular therapy with bevacizumab and cannabinoids for glioblastomaAvastin / Sativex / Osmitrol injection 20% ยท Glioblastoma ยท Protocol NOVA-GBM-PH1-001St Michaels HospitalPending
Oct 15, 2026A phase 3 open label randomized study of telisotuzumab adizutecan compared to standard of care in subjects with previously treated, EGFR wildtype, locallyโ€ฆTelisotuzumab adizutecan (ABBV-400) ยท Non-small cell lung cancer ยท Protocol M26-167AbbViePending
Oct 15, 2026An open-label randomized phase 2 study to evaluate safety and efficacy of patritumab deruxtecan plus pembrolizumab administered either before or afterโ€ฆPatritumab deruxtecan (MK-1022) / Pembrolizumab (MK-3475) ยท Breast cancer ยท Protocol MK-1022-010Merck & Co. (MSD)Pending
Oct 14, 2026A single-arm, multicenter, phase III study to assess efficacy, pharmacokinetics, safety and tolerability of zigakibart in pediatric patients with primaryโ€ฆZigakibart (FUB523) ยท Immunoglobulin A nephropathy ยท Protocol CFUB523B12301Novartis PharmaceuticalsPending
Oct 14, 2026A phase I/ib, multi-center, open-label, dose escalation and dose expansion study of FVY281 as monotherapy in adult participants with relapsed/refractory acuteโ€ฆFVY281 / Azacitidine ยท Acute myeloid leukemia ยท Protocol CFVY281A12101Novartis PharmaceuticalsPending
Oct 13, 2026Investigating the interplay between faah and opioid misuse in chronic non-cancer pain (CNCP): positron emission tomography studies with [11c]curb[11C]CURB ยท Pain ยท Protocol CAMHPET-CTA-153Centre for Addiction and Mental HealthOngoing
Oct 9, 2026Actfirst: a phase III, open-label, multi-center, randomized study comparing AAA817+arpi versus standard of care in adult participants with psma-positiveโ€ฆ[225AC]AC-PSMA-617 (AAA817) / Zytiga / Xtandi ยท Prostate cancer metastatic castrationโ€ฆ ยท Protocol CAAA817B12301Novartis PharmaceuticalsPending
Oct 9, 2026A phase 3, open-label study of ivonescimab vs durvalumab as consolidation therapy in patients with locally advanced, unresectable NSCLC (stage iii) who haveโ€ฆIvonescimab ยท Non-small cell lung cancer ยท Protocol SMT112-3010Summit Therapeutics Inc.Pending
Oct 2, 2026A phase I, open-label, multi-center, dose escalation study to evaluate the safety, pk, and pd of AZD6750 in participants with chronic hepatitis B on standardโ€ฆAZD6750 ยท Chronic hepatitis B ยท Protocol D7351C00001AstraZeneca PharmaceuticalsPending
Oct 2, 2026A phase 2/3 multicenter, randomized, open-label study of ASP-1929 photoimmunotherapy in combination with pembrolizumab versus standard of care in theโ€ฆASP-1929 (CETUXIMAB-IR700) ยท Squamous cell carcinoma of the head andโ€ฆ ยท Protocol ASP-1929-381Rakuten Medical, Inc.Pending
Oct 1, 2026A phase 3 registrational study to assess the efficacy, safety and tolerability of OCU410 for geographic atrophy secondary to dry age-related macularโ€ฆOCU410 (adeno-associated viral vector 5 human rora (AAV5-HRORA)) ยท Wet age-related macular degeneration ยท Protocol OCU410-301Ocugen, IncPending
Oct 1, 2026Volatile anesthetic pharmacokinetics during extracorporeal membrane oxygenationSevoflurane ยท Acute respiratory distress syndromeโ€ฆ ยท Protocol 22-6007University Health NetworkPending
Oct 1, 2026Bridge study: buprenorphine xr real-world induction, dosing, and gradual evaluationBuprenorphine ยท Opioid use disorder ยท Protocol HREBA.CTC-26-0111Dr. Navneet Singh KhosaPending
Oct 1, 2026A randomized trial of RIPK2 inhibitor OD-001 in combination with vedolizumab for moderately to severely active ulcerative colitisOD-001 (OD-07656) / Vedolizumab ยท Ulcerative colitis ยท Protocol OD-001-202Odyssey TherapeuticsPending
Oct 1, 2026A phase 1 safety and feasibility trial of focused ultrasound for the treatment of high-grade glioma in patients undergoing standard chemotherapy (GB7260)Perflutren (perfluoropropane) ยท Glioblastoma ยท Protocol GB-7260Sunnybrook Research InstitutePending
Sep 29, 2026A two-part, phase 2b/phase 3 double-blinded, randomized study of IPN60340 in combination with azacitidine and venetoclax versus placebo in combination withโ€ฆIPN60340 ยท Acute myeloid leukemia ยท Protocol CLIN-60340-450IpsenPending
Sep 29, 2026A randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy, safety and pharmacokinetics of LP-003 in peanut allergyโ€ฆLP-003 / Peanut powder / Oat powder ยท Penicillin allergy ยท Protocol P10-LP003-10Longbio Pharma (Suzhou) Co., LtdOngoing
Sep 28, 2026A phase 2, multicenter, double-blind, randomized, placebo-controlled, parallel-group study with an open-label treatment period to evaluate the efficacy andโ€ฆAGN-151607-DP (gemibotulinumtoxina) ยท Major depressive disorder ยท Protocol M26-083AbbViePending

Phase I to III drug trials Health Canada authorized with a No Objection Letter since April 2013; device and natural health product trials are not in the database, and it gives no phase. The sponsor is the company named on the trial's investigational products. Search a protocol number on Health Canada's site for its sites and contacts. Refreshed weekly. Health Canada, Clinical Trials Database

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.